Scotiabank increased its price target for Merck & Co. (MRK) to $180.00 from $155.00. This suggests a potential upside of approximately 22.8%. The firm maintained its "sector outperform" rating on Merck's shares.
The analyst action reflects a positive outlook for Merck's future performance. The updated price target ranks among the higher targets on Wall Street for the company. This contributes to a consensus "Moderate Buy" rating among analysts.